Phase 3 Pancreatic Cancer Trial, Recruiting NCT07562152 Sponsor: Immuneering Corporation Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Phase 3 Pancreatic Cancer Trial, Recruiting

NCT07562152
Recruiting Phase 3 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older
  • People who have been diagnosed with metastatic pancreatic adenocarcinoma (a specific type of pancreatic cancer that has spread to other parts of the body), confirmed within the last 12 weeks before screening
  • People whose general physical health and ability to carry out daily activities meets a certain standard, rated 0 or 1 on a scale used by doctors called the ECOG scale (meaning fully active or restricted in strenuous activity but able to do light work)
  • People who have not yet received any systemic anti-cancer treatment (such as chemotherapy) for this condition
  • People who have at least one area of cancer that can be measured on a scan, based on standard medical guidelines called RECIST v1.1
  • People whose liver, kidneys, blood clotting, and other organ functions meet the levels required by the trial protocol

Who may not be able to join:

  • People who are unable to swallow tablets or capsules taken by mouth
  • People whose pancreatic cancer is a different type, specifically squamous, adenosquamous, neuroendocrine (including carcinoid or islet cell), or acinar carcinoma
  • People whose cancer has not spread beyond the local area (locally advanced disease only, without spread to other parts of the body)
  • People who have cancer that has spread to the brain or central nervous system, where those metastases are causing symptoms, have not been treated, or are actively getting worse

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 860-321-1302

Australian sites

Calvary Mater Newcastle, Waratah, New South Wales
Icon Cancer Centre - Chermside, Chermside, Queensland

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Immuneering Corporation
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
1 June 2028

Where this trial is recruiting

🇦🇺 Australia 🇺🇸 United States

2 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Overall Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov